Tag: Posaconazole

1. Posaconazole  was non-inferior to voriconazole with respect to all-cause mortality at day 42 (15% vs. 21%, respectively). 2. Incidence of treatment-related adverse events was lower for posaconazole than voriconazole.  Evidence Rating Level: 2 (Good)  Study Rundown: Invasive aspergillosis (IA) is a life-threatening infection that commonly occurs in patients with immunosuppression. Currently, voriconazole serves as...
1. Posaconazole  was non-inferior to voriconazole with respect to all-cause mortality at day 42 (15% vs. 21%, respectively). 2. Incidence of treatment-related adverse events was lower for posaconazole than voriconazole.  Evidence Rating Level: 2 (Good)  Study Rundown: Invasive aspergillosis (IA) is a life-threatening infection that commonly occurs in patients with immunosuppression. Currently,...
Image: PD In this section, we highlight the key high-impact studies, updates, and analyses published in medicine during the past week. Pharmacotherapy for Adults With Alcohol Use Disorders in Outpatient Settings Despite continued high rates of morbidity and early mortality caused by alcohol use disorders (AUDs), less than 10% of patients with...
Image: PD  1. Posaconazole showed anti-trypanosomal activity, but there was a high rate of treatment failure 10 months after treatment.  2. Posaconazole had fewer serious adverse events than benznidazole.  Evidence Rating Level: 1 (Excellent)  Study Rundown: Chagas disease is caused by the parasite Trypanosoma cruzi which in its chronic form leads to cardiac...